Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas / Differential effects on serum IGF-1 of tibolone (5 mg/day) vs combined continuous estrogen/progestagen in post menopausal women
Rev. méd. Chile
;
131(10): 1151-1156, oct. 2003.
Artigo
em Espanhol
| LILACS
| ID: lil-355981
ABSTRACT
BACKGROUND:
Tibolone has estrogenic, androgenic and progestational effects and is used in post menopausal women. It apparently has weaker effects on endometrial proliferation and mammary stimulation than conventional hormone replacement therapy.AIM:
To compare the metabolic effects of tibolone (5 mg/day) and continuous combined conjugated estrogens/medroxyprogesterone acetate in postmenopausal women. PATIENTS ANDMETHODS:
Postmenopausal women, aged 45 to 60 years old, receiving estradiol valerate and medroxyprogesterone were included in the study. After a two months wash out period, in a double blind fashion, they were randomly assigned to oral tibolone 5 mg/day or equine conjugated estrogens 0.625 mg + medroxiprogesterone acetate 2.5 mg/day (ECE/MPA). At baseline, 30 and 45 days of treatment, fasting serum osteocalcin, somatomedin C (IGF-1, insulin-like growth factor 1), growth hormone (GH), and follicle stimulating hormone and first morning urine calcium and creatinine were measured.RESULTS:
Thirty women were studied. There was more than 50 per cent fall in urine calcium with either tibolone or ECE/MPA, while fasting GH or osteocalcin did not show significant changes. Serum IGF-1 increased significantly with tibolone at basal, 30 (+109 per cent) and 45 days of treatment and did not change in the ECE/MPA group.CONCLUSIONS:
Tibolone (5 mg/day) and ECE/MPA induced a similar reduction in urinary calcium. Tibolone increased serum IGF-1 levels. This may be due to undetected increment of overall GH secretion or to a specific action or IGF-1 generation from the liver and appears to be a novel differential effect of tibolone.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Fator de Crescimento Insulin-Like I
/
Pós-Menopausa
/
Anticoncepcionais Femininos
/
Moduladores de Receptor Estrogênico
/
Estradiol
/
Norpregnenos
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo observacional
Limite:
Feminino
/
Humanos
Idioma:
Espanhol
Revista:
Rev. méd. Chile
Assunto da revista:
Medicina
Ano de publicação:
2003
Tipo de documento:
Artigo
País de afiliação:
Chile
Instituição/País de afiliação:
Universidad de Chile/CL
Similares
MEDLINE
...
LILACS
LIS